Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study

Onderdijk, Armanda; IJpma, Arne; Menting, S.P.; Baerveldt, Ewout M.; Prens, Errol P.

doi:10.1111/bjd.13997

Cited by 8 publications

(5 citation statements)

References 12 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we cannot exclude the possibility that the associations observed are because of factors other than the increased IFN-γ. Moreover, our results are supported by a Dutch pilot study 32 in which patients who responded to ustekinumab had a strong IFN signature compared with that of nonresponders.…”

Section: Study Populationsupporting

confidence: 80%

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

et al. 2017

View full text Add to dashboard Cite

Section: Study Populationsupporting

confidence: 80%

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

et al. 2017

View full text Add to dashboard Cite

“…Therefore, even with substantial effect sizes, a prediction model containing additional variables must be sought. Such a model may also include other markers such as at the epigenetic, immunological or microbial level …”

Section: Discussionmentioning

confidence: 72%

Polymorphisms inCD84,IL12BandTNFAIP3are associated with response to biologics in patients with psoriasis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…With our proteomics substudy, we intended to pave the way in discovering pharmacodynamic signatures capable of predicting GUS response. Despite using a sample size comparable to other Olink® studies [36][37][38][39][40] and that the Olink® assay was able to identify DEPs (e.g. between psoriasis patients and healthy controls), we could not identify predictive candidates with the chosen protein panel.…”

Section: Discussionmentioning

confidence: 94%

Exposure–response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis

Soenen,

Schots,

Wang

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundResponse to biologics in psoriasis varies in real‐world settings. Serum biomarkers could aid biologic selection and dose modifications to improve patient outcomes while encouraging cost‐effective care.ObjectivesTo explore the exposure–response relationship for guselkumab (GUS), to define a GUS concentration target for optimal response and to evaluate the potential of serum protein levels as predictive biomarker candidates.MethodsThis is a prospective, multicentric, cohort study in psoriasis patients treated with GUS. Serum GUS trough concentrations (TCs) collected at multiple timepoints were measured using an in‐house immunoassay. Next, proximity extension assay technology (Target 96 Inflammation Panel Olink®) was used to measure serum protein levels in a subcohort including 38 GUS patients (week 0 and week 4), six psoriasis patients naive for systemic treatment and four healthy controls.ResultsSeventy‐five patients participated and 400 samples were collected. Guselkumab TCs and clinical response were correlated at week 4, week 12 and in steady‐state (≥20 weeks). Optimal responders (Psoriasis Area and Severity Index [PASI] ≤ 2) had significantly higher TCs than suboptimal responders from week 4 onwards in treatment. An optimal steady‐state TC of 1.6 μg/mL was defined. Although TC and absolute PASI were lower and worse, respectively, in patients weighing ≥90 kg, clinical outcomes referred to desirable to excellent PASI ranges. Therefore, we do not recommend systematically higher GUS doses in obese patients. We could not reveal early differentially expressed proteins to distinguish future optimal from suboptimal responders.ConclusionsWe demonstrated an exposure–response relationship for GUS and an optimal steady‐state TC of 1.6 μg/mL in real‐world psoriasis patients. Hereby, we deliver more evidence that therapeutic drug monitoring poses a promising strategy in optimizing GUS treatment. No biomarker candidates were identified through serum proteomics. We propose protein screening should be repeated in larger cohorts to continue the quest for predictive biomarkers.

show abstract

Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study

Cited by 8 publications

References 12 publications

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

Polymorphisms inCD84,IL12BandTNFAIP3are associated with response to biologics in patients with psoriasis

Exposure–response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis

Contact Info

Product

Resources

About